Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Anti-HER2 therapies have markedly improved prognosis of HER2-positive breast cancer.
However, different mechanisms play a role in treatment resistance. Here, we identified AXL …

Mutations in STK11/LKB1 in non-small cell lung cancer (NSCLC) are associated with poor
patient responses to immune checkpoint blockade (ICB), and introduction of a Stk11/Lkb1 …

The therapeutic efficacy of current cancer vaccines is far from optimal, mainly because of
insufficient induction of antigen-specific T cells and because tumor cells can hijack …

Favorable clinical evidence suggests that the next trend in new treatments for advanced non-
small cell lung cancer (NSCLC) will be combination therapies. However, inevitable …

Many signaling pathways are dysregulated in cancer cells and the host tumor
microenvironment. Aberrant receptor tyrosine kinase (RTK) pathways promote cancer …